Clawback to rise 41 pct this year

Pharmaceutical companies are set for a far greater burden this year due to the size of the dreaded "clawback" - i.e. the cash they will have to return to the state - according to projections by the National Organization for the Provision of Healthcare Services (EOPYY).

The main reasons for the projected increase in the dues, expected to top 40 percent year-on-year, are the rise in the number of uninsured patients, higher expenditure on vaccines and the continuing excess of prescriptions.

EOPYY estimates, which concur with those of the industry, put the clawback dues in the second half of the year at 60 percent above those during the same period last year, at about 450 million euros, against 281 million in 2018. Therefore sector representatives expect this year's clawback to total 810 million euros, up 41 percent from last year's 572 million euros, after coming to 360...

Continue reading on: